Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Delpharm to Manufacture Pfizer/BioNTech mRNA Vax in France | Contract Pharma

What are you searching for?

Sign in

Delpharm to Manufacture Pfizer/BioNTech mRNA Vax in France

Will begin manufacturing BNT 162b2 in April 2021 and will produce tens of millions of doses.

By: Contract Pharma

Contract Pharma Staff

Delpharm, a CDMO headquartered in France, has entered into an agreement with BioNTech to manufacture the BNT 162b2 vaccine to prevent Coronavirus infection at its plant in Saint-Rémy-sur-Avre (Normandy).

Delpharm will begin manufacturing in April 2021 and will produce tens of millions of doses.

Stéphane Lepeu, Delpharm’s Chief Commercial Officer, said, “Delpharm is proud to be the first company selected to produce this vaccine in France.”

This agreement will enable Delpharm to recruit an additional 40 to 60 people at its Saint-Rémy-sur-Avre site.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics